Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy

Cell

Volumn 170, Issue 3, 2017, Pages 548-563.e16

  Yu, TaChung ^a   Guo, Fangfang ^a   Yu, Yanan ^a   Sun, Tiantian ^a   Ma, Dan ^a   Han, Jixuan ^a   Qian, Yun ^a   Kryczek, Ilona ^b   Sun, Danfeng ^a,b   Nagarsheth, Nisha ^b   Chen, Yingxuan ^a   Chen, Haoyan ^a   Hong, Jie ^a   Zou, Weiping ^b   Fang, Jing Yuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

autophagy; chemoresistance; Colorectal cancer; F.nucleatum; miRNA; recurrence; Toll like receptor

Indexed keywords

CAPECITABINE; CHLOROQUINE; FLUOROURACIL; MICRORNA; MICRORNA 18A; MICRORNA 4802; MYELOID DIFFERENTIATION FACTOR 88; OXALIPLATIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN18A MICRORNA, HUMAN; MIRN4802 MICRORNA, HUMAN; PLATINUM DERIVATIVE; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MEGADOSE; FEMALE; FUSOBACTERIUM NUCLEATUM; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE FLORA; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR VOLUME; ANIMAL; CANCER TRANSPLANTATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE; METABOLISM; PATHOLOGY; PHYSIOLOGY; RECURRENT DISEASE; TUMOR MICROENVIRONMENT; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CAPECITABINE; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FUSOBACTERIUM NUCLEATUM; GASTROINTESTINAL MICROBIOME; HETEROGRAFTS; MICE; MICRORNAS; NEOPLASM TRANSPLANTATION; PLATINUM COMPOUNDS; RECURRENCE; TOLL-LIKE RECEPTORS; TUMOR MICROENVIRONMENT;

EID: 85026371130     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.07.008     Document Type: Article

References (50)

1. Abed, J., Emgård, J.E., Zamir, G., Faroja, M., Almogy, G., Grenov, A., Sol, A., Naor, R., Pikarsky, E., Atlan, K.A., et al. Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. Cell Host Microbe 20 (2016), 215–225.
2. Abreu, M.T., Peek, R.M. Jr., Gastrointestinal malignancy and the microbiome. Gastroenterology 146 (2014), 1534–1546 e1533.
3. Anders, S., McCarthy, D.J., Chen, Y., Okoniewski, M., Smyth, G.K., Huber, W., Robinson, M.D., Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat. Protoc. 8 (2013), 1765–1786.
4. Anders, S., Pyl, P.T., Huber, W., HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics 31 (2015), 166–169.
5. Arthur, J.C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J.M., Fan, T.J., Campbell, B.J., Abujamel, T., Dogan, B., Rogers, A.B., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338 (2012), 120–123.
6. Bardelli, A., Siena, S., Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28 (2010), 1254–1261.
7. Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell 136 (2009), 215–233.
8. Bertotti, A., Sassi, F., Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. Clin. Cancer Res. 21 (2015), 3377–3383.
9. Cartwright, T.H., Treatment decisions after diagnosis of metastatic colorectal cancer. Clin. Colorectal Cancer 11 (2012), 155–166.
10. Castellarin, M., Warren, R.L., Freeman, J.D., Dreolini, L., Krzywinski, M., Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R.A., Holt, R.A., Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22 (2012), 299–306.
11. Chen, H.M., Yu, Y.N., Wang, J.L., Lin, Y.W., Kong, X., Yang, C.Q., Yang, L., Liu, Z.J., Yuan, Y.Z., Liu, F., et al. Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am. J. Clin. Nutr. 97 (2013), 1044–1052.
12. Dahan, L., Sadok, A., Formento, J.L., Seitz, J.F., Kovacic, H., Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br. J. Pharmacol. 158 (2009), 610–620.
13. Dallas, N.A., Xia, L., Fan, F., Gray, M.J., Gaur, P., van Buren, G. 2nd, Samuel, S., Kim, M.P., Lim, S.J., Ellis, L.M., Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 69 (2009), 1951–1957.
14. Esteller, M., Epigenetics in cancer. N. Engl. J. Med. 358 (2008), 1148–1159.
15. Garrett, W.S., Cancer and the microbiota. Science 348 (2015), 80–86.
16. Hänzelmann, S., Castelo, R., Guinney, J., GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics, 14, 2013, 7.
17. Iida, N., Dzutsev, A., Stewart, C.A., Smith, L., Bouladoux, N., Weingarten, R.A., Molina, D.A., Salcedo, R., Back, T., Cramer, S., et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342 (2013), 967–970.
18. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J., Cancer statistics, 2009. CA Cancer J. Clin. 59 (2009), 225–249.
19. Jeong, H., Lim, Y.W., Yi, H., Sekiguchi, Y., Kamagata, Y., Chun, J., Anaerosporobacter mobilis gen. nov., sp. nov., isolated from forest soil. Int. J. Syst. Evol. Microbiol. 57 (2007), 1784–1787.
20. Kelland, L., The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7 (2007), 573–584.
21. Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., Salzberg, S.L., TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol., 14, 2013, R36.
22. Kostic, A.D., Gevers, D., Pedamallu, C.S., Michaud, M., Duke, F., Earl, A.M., Ojesina, A.I., Jung, J., Bass, A.J., Tabernero, J., et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22 (2012), 292–298.
23. Krek, A., Grün, D., Poy, M.N., Wolf, R., Rosenberg, L., Epstein, E.J., MacMenamin, P., da Piedade, I., Gunsalus, K.C., Stoffel, M., Rajewsky, N., Combinatorial microRNA target predictions. Nat. Genet. 37 (2005), 495–500.
24. Linardou, H., Dahabreh, I.J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C.A., Murray, S., Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9 (2008), 962–972.
25. Liu, H., Redline, R.W., Han, Y.W., Fusobacterium nucleatum induces fetal death in mice via stimulation of TLR4-mediated placental inflammatory response. J. Immunol. 179 (2007), 2501–2508.
26. Love, M.I., Huber, W., Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 2014, 550.
27. Man, S.M., Zhu, Q., Zhu, L., Liu, Z., Karki, R., Malik, A., Sharma, D., Li, L., Malireddi, R.K., Gurung, P., et al. Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer. Cell 162 (2015), 45–58.
28. Mima, K., Nishihara, R., Qian, Z.R., Cao, Y., Sukawa, Y., Nowak, J.A., Yang, J., Dou, R., Masugi, Y., Song, M., et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 65 (2016), 1973–1980.
29. Moutinho, C., Martinez-Cardús, A., Santos, C., Navarro-Pérez, V., Martínez-Balibrea, E., Musulen, E., Carmona, F.J., Sartore-Bianchi, A., Cassingena, A., Siena, S., et al. Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. J. Natl. Cancer Inst., 106, 2014 djt322–djt322.
30. Nguyen, H.T., Dalmasso, G., Müller, S., Carrière, J., Seibold, F., Darfeuille-Michaud, A., Crohn's disease-associated adherent invasive Escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy. Gastroenterology 146 (2014), 508–519.
31. Rhee, K.J., Wu, S., Wu, X., Huso, D.L., Karim, B., Franco, A.A., Rabizadeh, S., Golub, J.E., Mathews, L.E., Shin, J., et al. Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect. Immun. 77 (2009), 1708–1718.
32. Rubinstein, M.R., Wang, X., Liu, W., Hao, Y., Cai, G., Han, Y.W., Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14 (2013), 195–206.
33. Schirmer, M., Smeekens, S.P., Vlamakis, H., Jaeger, M., Oosting, M., Franzosa, E.A., Jansen, T., Jacobs, L., Bonder, M.J., Kurilshikov, A., Fu, J., Joosten, L.A., Zhernakova, A., Huttenhower, C., Wijmenga, C., Netea, M.G., Xavier, R.J., Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell 167(4) (2016), 1125–1136 e1128.
34. Schwabe, R.F., Jobin, C., The microbiome and cancer. Nat. Rev. Cancer 13 (2013), 800–812.
35. Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W.S., Huttenhower, C., Metagenomic biomarker discovery and explanation. Genome Biol., 12, 2011, R60.
36. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J. Clin. 63 (2013), 11–30.
37. Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M., Benyamin, F.W., Lei, Y.M., Jabri, B., Alegre, M.L., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350 (2015), 1084–1089.
38. Song, J., Qu, Z., Guo, X., Zhao, Q., Zhao, X., Gao, L., Sun, K., Shen, F., Wu, M., Wei, L., Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy 5 (2009), 1131–1144.
39. Sun, T.T., Tang, J.Y., Du, W., Zhao, H.J., Zhao, G., Yang, S.L., Chen, H.Y., Hong, J., Fang, J.Y., Bidirectional regulation between TMEFF2 and STAT3 may contribute to Helicobacter pylori-associated gastric carcinogenesis. Int. J. Cancer 136 (2015), 1053–1064.
40. Van Geelen, C.M., de Vries, E.G., de Jong, S., Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist. Updat. 7 (2004), 345–358.
41. Vétizou, M., Pitt, J.M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M.P., Duong, C.P., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350 (2015), 1079–1084.
42. Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D.P., Pfirschke, C., Engblom, C., Pittet, M.J., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342 (2013), 971–976.
43. Walko, C.M., Lindley, C., Capecitabine: a review. Clin. Ther. 27 (2005), 23–44.
44. Wang, W., Kryczek, I., Dostál, L., Lin, H., Tan, L., Zhao, L., Lu, F., Wei, S., Maj, T., Peng, D., et al. Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell 165 (2016), 1092–1105.
45. Weichert, W., Röske, A., Niesporek, S., Noske, A., Buckendahl, A.C., Dietel, M., Gekeler, V., Boehm, M., Beckers, T., Denkert, C., Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 14 (2008), 1669–1677.
46. Xiong, H., Hong, J., Du, W., Lin, Y.W., Ren, L.L., Wang, Y.C., Su, W.Y., Wang, J.L., Cui, Y., Wang, Z.H., Fang, J.Y., Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J. Biol. Chem. 287 (2012), 5819–5832.
47. Yu, Y.N., Yu, T.C., Zhao, H.J., Sun, T.T., Chen, H.M., Chen, H.Y., An, H.F., Weng, Y.R., Yu, J., Li, M., et al. Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. Oncotarget 6 (2015), 32013–32026.
48. Zhou, C., Zhong, W., Zhou, J., Sheng, F., Fang, Z., Wei, Y., Chen, Y., Deng, X., Xia, B., Lin, J., Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer cells. Autophagy 8 (2012), 1215–1226.
49. Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., Kroemer, G., Cancer and the gut microbiota: an unexpected link. Sci. Transl. Med., 7, 2015, 271ps1.
50. Zou, W., Wolchok, J.D., Chen, L., PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med., 8, 2016, 328rv4.